In last trading session, BioXcel Therapeutics Inc (NASDAQ:BTAI) saw 1.16 million shares changing hands with its beta currently measuring -0.02. Company’s recent per share price level of $2.03 trading at -$0.02 or -0.98% at ring of the bell on the day assigns it a market valuation of $12.29M. That closing price of BTAI’s stock is at a discount of -1137.44% from its 52-week high price of $25.12 and is indicating a premium of 42.36% from its 52-week low price of $1.17. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.34 million shares which gives us an average trading volume of 238.61K if we extend that period to 3-months.
For BioXcel Therapeutics Inc (BTAI), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.75. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -1.56 in the current quarter.
BioXcel Therapeutics Inc (NASDAQ:BTAI) trade information
Upright in the red during last session for losing -0.98%, in the last five days BTAI remained trading in the green while hitting it’s week-highest on Wednesday, 06/25/25 when the stock touched $2.03 price level, adding 8.56% to its value on the day. BioXcel Therapeutics Inc’s shares saw a change of -89.34% in year-to-date performance and have moved 17.34% in past 5-day. BioXcel Therapeutics Inc (NASDAQ:BTAI) showed a performance of 46.04% in past 30-days. Number of shares sold short was 0.32 million shares which calculate 0.76 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 10 to the stock, which implies a rise of 79.7% to its current value. Analysts have been projecting 1 as a low price target for the stock while placing it at a high target of 25. It follows that stock’s current price would jump 50.74% in reaching the projected high whereas dropping to the targeted low would mean a gain of 50.74% for stock’s current value.
BioXcel Therapeutics Inc (BTAI) estimates and forecasts
This year revenue growth is estimated to fall -43.81% from the last financial year’s standing.
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 206k for the same. And 3 analysts are in estimates of company making revenue of 256k in the next quarter. Company posted 1.1M and 214k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 6.20% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 73.84% while estimates for its earnings growth in next 5 years are of 53.72%.
BioXcel Therapeutics Inc (NASDAQ:BTAI)’s Major holders
Insiders are in possession of 8.65% of company’s total shares while institution are holding 11.02 percent of that, with stock having share float percentage of 12.06%. Investors also watch the number of corporate investors in a company very closely, which is 11.02% institutions for BioXcel Therapeutics Inc that are currently holding shares of the company. ARMISTICE CAPITAL, LLC is the top institutional holder at BTAI for having 2.99 million shares of worth $3.82 million. And as of 2024-06-30, it was holding 0.4638 of the company’s outstanding shares.
The second largest institutional holder is FMR LLC, which was holding about 2.21 million shares on 2024-06-30. The number of shares represents firm’s hold over 0.3424 of outstanding shares, having a total worth of $2.82 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 18.33 shares of worth $37211.0 or 0.30% of the total outstanding shares. The later fund manager was in possession of 14.23 shares on Apr 30, 2025 , making its stake of worth around $28884.0 in the company or a holder of 0.23% of company’s stock.
